RxDoctor Payments Data

Michael Montgomery, DO

Family Medicine · Clarksburg, WVNPI 1366553166

Payments from drug & device makers

$1,970in general payments, 2019–2025

Across 112 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$456
  • AbbVie$309
  • Novo Nordisk$268
  • Lilly USA, LLC$212
  • Amarin Pharma, Inc.$99
  • GSK$98
  • plus $528 from 17 others

What the payments were for

  • Food & beverage$1,964100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,970 in reported general payments places this provider in the 75th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$20,721
Medicare patients
120
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$50,429
JardianceEmpagliflozin29$39,529
MounjaroTirzepatide40$37,153
TrulicityDulaglutide22$34,644
EliquisApixaban34$33,286
FarxigaDapagliflozin Propanediol22$23,579
Tresiba Flextouch U-200Insulin Degludec17$21,296
XareltoRivaroxaban28$16,982
GlyxambiEmpagliflozin/Linagliptin24$16,556
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,958
Combivent RespimatIpratropium/Albuterol Sulfate12$6,670
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,671
Rosuvastatin Calcium253$2,746
Novolog FlexpenInsulin Aspart14$2,700
Levothyroxine Sodium178$2,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$212$71,79662 claims
Boehringer IngelheimJardiance, Glyxambi, Combivent Respimat$86$62,75565 claims
Novo NordiskOzempic$268$50,42930 claims
PfizerEliquis$37$33,28634 claims
AstraZenecaFarxiga$456$23,57922 claims
GSKTrelegy Ellipta$98$11,95811 claims
AbbVieSynthroid$309$1,99418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Clarksburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →